C Majós1,2, M Cos3, S Castañer3, A Pons3, M Gil4, A Fernández-Coello5, M Macià6, J Bruna7,8, C Aguilera3,2. 1. From the Departments of Radiology, Institut de Diagnòstic per la Imatge (C.M., M.C., S.C., A.P., C.A.) cmajos@bellvitgehospital.cat. 2. Centro de Investigación Red en Bioingeniería, Biomateriales y Nanomedicina (C.M., C.A.), Cerdanyola del Vallès, Spain. 3. From the Departments of Radiology, Institut de Diagnòstic per la Imatge (C.M., M.C., S.C., A.P., C.A.). 4. Medical Oncology, Institut Català d'Oncologia L'Hospitalet (M.G.). 5. Neurosurgery (A.F.-C.). 6. Radiotherapy Oncology, Institut Català d'Oncologia L'Hospitalet (M.M.). 7. Neurology (J.B.), Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain. 8. Institut d'Investigació Biomèdica de Bellvitge, IDIBELL (J.B.), L'Hospitalet de Llobregat, Spain.
Abstract
BACKGROUND AND PURPOSE: Current protocols in patients with glioblastoma include performing an MR examination shortly after surgery and then 2-6 weeks after ending concomitant chemoradiotherapy. The assessment of this first postradiotherapy examination is challenging because the pseudoprogression phenomenon may appear. The aim of this study was to explore if performing an MR examination shortly before radiation therapy (preradiotherapy MR imaging) could improve the radiologic assessment of patients with glioblastoma. MATERIALS AND METHODS: A preradiotherapy MR imaging examination was prospectively performed before the start of radiation therapy in 28 consecutive patients with glioblastoma who had undergone surgical resection. Tumor response to chemoradiotherapy was assessed twice: with the early postoperative MR examination as baseline and with the preradiotherapy MR imaging examination as baseline. In addition, tumor growth in the preradiotherapy MR imaging examination was evaluated, and its correlation with patient survival was assessed with Kaplan-Meier analysis and Cox regression. RESULTS: Tumor progression after radiation therapy was found in 16 patients, corresponding to pseudoprogression in 7 of them (44%). Four assessments of pseudoprogression switched to partial response or stable disease when preradiotherapy MR imaging was the baseline examination, and the ratio of pseudoprogression was reduced to 25% (3 of 12). Significant differences in survival were found when patients were stratified according to the pattern of tumor growth on preradiotherapy MR imaging (median overall survival "no-growth," 837 days; "focal-growth," 582 days; "global-growth," 344 days; P = .001). CONCLUSIONS: Performing a preradiotherapy MR imaging examination may improve the clinical management of patients with glioblastoma by reducing the ratio of pseudoprogression assessments and providing prognostic information.
BACKGROUND AND PURPOSE: Current protocols in patients with glioblastoma include performing an MR examination shortly after surgery and then 2-6 weeks after ending concomitant chemoradiotherapy. The assessment of this first postradiotherapy examination is challenging because the pseudoprogression phenomenon may appear. The aim of this study was to explore if performing an MR examination shortly before radiation therapy (preradiotherapy MR imaging) could improve the radiologic assessment of patients with glioblastoma. MATERIALS AND METHODS: A preradiotherapy MR imaging examination was prospectively performed before the start of radiation therapy in 28 consecutive patients with glioblastoma who had undergone surgical resection. Tumor response to chemoradiotherapy was assessed twice: with the early postoperative MR examination as baseline and with the preradiotherapy MR imaging examination as baseline. In addition, tumor growth in the preradiotherapy MR imaging examination was evaluated, and its correlation with patient survival was assessed with Kaplan-Meier analysis and Cox regression. RESULTS:Tumor progression after radiation therapy was found in 16 patients, corresponding to pseudoprogression in 7 of them (44%). Four assessments of pseudoprogression switched to partial response or stable disease when preradiotherapy MR imaging was the baseline examination, and the ratio of pseudoprogression was reduced to 25% (3 of 12). Significant differences in survival were found when patients were stratified according to the pattern of tumor growth on preradiotherapy MR imaging (median overall survival "no-growth," 837 days; "focal-growth," 582 days; "global-growth," 344 days; P = .001). CONCLUSIONS: Performing a preradiotherapy MR imaging examination may improve the clinical management of patients with glioblastoma by reducing the ratio of pseudoprogression assessments and providing prognostic information.
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Andrea Pirzkall; Colleen McGue; Suja Saraswathy; Soonmee Cha; Raymond Liu; Scott Vandenberg; Kathleen R Lamborn; Mitchel S Berger; Susan M Chang; Sarah J Nelson Journal: Neuro Oncol Date: 2009-12 Impact factor: 12.300
Authors: M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya Journal: J Neurosurg Date: 2001-08 Impact factor: 5.115
Authors: C B Scott; C Scarantino; R Urtasun; B Movsas; C U Jones; J R Simpson; A J Fischbach; W J Curran Journal: Int J Radiat Oncol Biol Phys Date: 1998-01-01 Impact factor: 7.038
Authors: Michael Weller; Martin van den Bent; Kirsten Hopkins; Jörg C Tonn; Roger Stupp; Andrea Falini; Elizabeth Cohen-Jonathan-Moyal; Didier Frappaz; Roger Henriksson; Carmen Balana; Olivier Chinot; Zvi Ram; Guido Reifenberger; Riccardo Soffietti; Wolfgang Wick Journal: Lancet Oncol Date: 2014-08 Impact factor: 41.316
Authors: Thierry Gorlia; Martin J van den Bent; Monika E Hegi; René O Mirimanoff; Michael Weller; J Gregory Cairncross; Elizabeth Eisenhauer; Karl Belanger; Alba A Brandes; Anouk Allgeier; Denis Lacombe; Roger Stupp Journal: Lancet Oncol Date: 2007-12-21 Impact factor: 41.316
Authors: C Balaña; A Estival; I Teruel; M Hardy-Werbin; J Sepulveda; E Pineda; M Martinez-García; O Gallego; R Luque; M Gil-Gil; C Mesia; S Del Barco; A Herrero; A Berrocal; P Perez-Segura; R De Las Penas; J Marruecos; R Fuentes; G Reynes; J M Velarde; A Cardona; E Verger; C Panciroli; S Villà Journal: Clin Transl Oncol Date: 2018-05-08 Impact factor: 3.405